Cash loans

I am going to give you a list of 3 Penny Stocks. All of these came across my radar and I wanted to share them with you. I know some of them may not be Penny Stocks To Watch anymore but they were at one point in time.

XJT – Up 100.30% in pre-market trading on 8/4/2010 on 309,000+ in volume.

*NEWS on 8/4/2010* Tripp Levy PLLC Investigates Buyout of ExpressJet By SkyWest

Trade Idea – We like this stock at short at 6.39 for a quick 5% brekdown. Keep this on your list of Penny Stocks to watch.

ExpressJet Holdings, Inc. owns strategic investments in the air transportation industry, and operates various divisions to leverage the assets of its subsidiaries, including ExpressJet Airlines, Inc. and ExpressJet Services, LLC. ExpressJet Airlines, Inc. serves 134 scheduled destinations in North America and the Caribbean with approximately 1,045 departures per day. The company has a capacity purchase agreement for Continental Airlines, Inc. (Continental); provides clients with customized 41-seat and 50-seat charter options (www.expressjet.com/charter); and offers third-party aviation services, including airport ground handling, aircraft maintenance, aircraft refurbishment work, and aircraft cleaning. As of December 31, 2009, it operated a fleet of 244 aircraft comprising 214 aircraft for Continental under the capacity purchase agreement, and 30 aircraft for corporate aviation under long-term agreements and other ad-hoc charter service arrangements. The company was founded in 1996 and is headquartered in Houston, Texas.

DEPO – Traded Up 20.49% in pre-market trading on 8/4/2010 on 50,800 + in volume.

*NEWS* Had News on 8-3/2010

Trade Idea – Keep this on your watch list for the remainder of 2010 and set your alert for 4.11. We think this stock will make a huge breakout run at 4.11.

Depomed, Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary oral drug delivery technologies in the United States. It markets GLUMETZA for the treatment of type 2 diabetes in the United States and Canada; and Proquin XR for the treatment of uncomplicated urinary tract infection in the United States. The company’s product candidates include DM-1796 for the treatment of postherpetic neuralgia, which has completed a Phase III clinical trial; Serada for the treatment of menopausal hot flashes, which has completed a Phase III clinical trial; DM-3458 for gastroesophageal reflux disease; and DM-1992 to treat Parkinson’s disease, which has completed a Phase I clinical trial. It sells its products to wholesalers and retail pharmacies. The company has collaboration and license agreements with Solvay Pharmaceuticals, Inc.; PharmaNova, Inc.; Santarus, Inc.; Merck & Co., Inc.; Covidien, Ltd.; TEVA Pharmaceuticals USA, Inc.; King Pharmaceuticals, Inc.; Esprit Pharma, Inc.; LG Life Sciences, Ltd.; Rottapharm/Madaus S.r.l.; PharmaNova, Inc.; and Supernus Pharmaceuticals, Inc. Depomed, Inc. was founded

XOMA – Up 8.26% in pre-market trading on 8/4/2010 on 544,000 + in volume.

*NEWS* No New News on 8/4/2010

Trade Idea Look For Momentum To continue. Make sure you put this on your list of Penny Stocks to Watch. This is still down 50% from the high. We like this around .41 to ride up for an EASY 10%.

XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies to treat inflammatory, autoimmune, infectious, and oncological diseases. The company receives royalties on products, such as LUCENTIS for the treatment of neovascular (wet) age-related macular degeneration; and CIMZIA for the treatment of rheumatoid arthritis and Crohn’s disease. Its products under development include XOMA 052, a monoclonal antibody for the treatment of Type 2 diabetes, rheumatoid arthritis, gout, and other diseases, which is in Phase II clinical studies; and XOMA 3AB, a biodefense anti-botulism antibody for the treatment of botulism poisoning. The company’s developing product also includes HCD122, a human anti-CD40 antagonist antibody for the treatment of B-cell mediated diseases, including malignancies and autoimmune diseases in Phase I/II clinical trials for various indications. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. The company has collaboration agreements with Kaketsuken; National Institute of Allergy and Infectious Diseases; SRI International; Genentech, Inc.; UCB Celltech; Takeda Pharmaceutical Company Limited; Schering-Plough Research Institute; Novartis AG; and Arana Therapeutics Limited. XOMA Ltd. was founded in 1981 and is headquartered in Berkeley, California.

For important information about forex managed accounts – please make sure to go through the webpage. The time has come when proper info is truly within one click, use this possibility.